Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways…
Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy
Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week…
3 Companies Redefining Healthcare Innovation
This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
FDA grants priority review for 3 psychedelic drugs in line with recent Donald Trump order
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression…